{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-037679","form_type":"8-K","ticker":"QCLS","cik":"0001321834","company_name":"Q/C TECHNOLOGIES, INC.","filed_at":"2023-10-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.600911+00:00","generated_at":"2026-06-09T19:54:08.981291+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MyMD Supera-CBD preclinical study shows rapid pain relief; Japanese patent granted","bullets":["Supera-CBD reduced acute inflammatory heat pain within 60 minutes; relief lasted up to five hours; traditional CBD had no effect.","Study at major academic center suggests Supera-CBD targets TRPV1 channels, potentially fewer side effects than opioids.","DEA determined Supera-CBD is not a controlled substance under the CSA; no scheduling required during development.","Japanese Patent No. 7293561 B2 issued for Supera-CBD as new molecular entity; company now holds 23 issued patents worldwide."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-037679","json":"https://secwatch.observer/filing/0001493152-23-037679.json","markdown":"https://secwatch.observer/filing/0001493152-23-037679.md","text":"https://secwatch.observer/filing/0001493152-23-037679.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1321834/000149315223037679/0001493152-23-037679-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1321834/000149315223037679/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T19:54:08.981291+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}